Rotkreuzklinikum Muenchen gGmbH
- Address
- lock Available on a paid plan
Breast Cancer Research
At Rotkreuzklinikum Muenchen gGmbH, most trials focus on neoplasms, especially a wide range of breast cancer subtypes. Research includes HER2-positive, HER2-negative, hormone receptor-positive, and triple-negative breast cancer, with studies designed to test new treatment options, improve recurrence prevention, and better control advanced disease.
- Testing newer therapies for early and advanced breast cancer
- Improving outcomes in HER2-positive and HR-positive disease
- Evaluating approaches for triple-negative breast cancer and high-risk recurrence settings
- Supporting more effective treatment selection after surgery or in metastatic disease
This work reflects a strong focus on personalized oncology, with many studies exploring ways to extend disease control and reduce the chance of relapse.
Hematology and Blood Cancer Studies
The site also conducts research in hemic and lymphatic diseases, including acute myeloid leukemia, multiple myeloma, and several forms of lymphoma. These trials aim to improve treatment effectiveness, deepen remission, and support better disease control in both newly diagnosed and relapsed settings.
- Evaluating new combinations for acute myeloid leukemia
- Studying treatment strategies in multiple myeloma, including relapsed and newly diagnosed cases
- Assessing therapies for aggressive and relapsed lymphoma
- Exploring better response and durability of benefit in blood cancers
These studies show a clear interest in advancing care for complex hematologic cancers, where treatment choice can strongly influence long-term outcomes.
Gynecologic and Other Solid Tumor Research
In addition to breast and blood cancers, the clinical research portfolio includes ovarian cancer, endometrial cancer, and germ cell tumors. The trials are aimed at testing new therapies, comparing treatment strategies, and improving survival in cancers that are often difficult to treat once advanced or recurrent.
- Investigating new options for ovarian cancer, including platinum-resistant disease
- Studying targeted approaches in endometrial cancer
- Comparing treatment strategies for germ cell tumors and seminoma
- Seeking better control of recurrent or metastatic gynecologic cancers
The Gynaecology department at this hospital contributes to research that combines treatment innovation with practical efforts to improve outcomes for patients facing advanced disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 87 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 87 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rotkreuzklinikum Muenchen gGmbH
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 87 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 9 | Unknown | 2016-01-11 | 2025-11-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.